New SARS-CoV-1 antibody available for vaccine researchers. A collaboration between PATH, Baylor College of Medicine and the Medicines and Healthcare products Regulatory Agency (MHRA) has made a monoclonal antibody (mAb) specific for SARS-CoV-1 available to researchers globally. This mAb can support the development of vaccines for SARS-CoV-1 and its evolving variants, as well as future characterization of novel and multivalent coronavirus vaccines. SARS-CoV-1, responsible for the 2003 SARS outbreak and a cousin of the SARS-CoV-2 virus that causes COVID-19, is a respiratory virus with a high mortality rate. There currently is no licensed vaccine to protect against the disease, despite its pandemic potential. In addition, there are limited SARS-CoV-1 specific antibodies available for vaccine development or therapeutic indications. Through this collaboration, scientists from Baylor produced high-quality recombinant SARS-CoV-1 RBD proteins, vaccinated mice, and tested selected mAbs for their functionality. The use of various techniques to characterize the binding sites and pseudovirus neutralization helped establish a toolbox of mAbs with identified key epitopes within the RBD and discriminate vaccine antigens. Selected hybridoma cultures were shipped to PATH for further screening and down-selection, validation, scale-up production, and distribution. Manufacturers can potentially use the resulting mAb to quantify SARS-CoV-1 spike protein in complex vaccine formulations. These efforts were conducted by: * Dr. Jeroen Pollet, associate professor in pediatric tropical medicine at Baylor; * Dr. Wen-Hsiang Chen, associate professor in pediatric tropical medicine at Baylor; * Dr. Uli Strych, associate professor in pediatric tropical medicine at Baylor and director for strategic initiatives and program development of the Texas Children's Center for Vaccine Development; and * Dr. Maria Elena Bottazzi, senior associate dean of the National School of Tropical Medicine at Baylor and co-director of the Texas Children's Center for Vaccine Development. "Access to well-characterized reference antibodies is essential for evaluating the much-needed emerging pan-coronavirus vaccine candidates and ensuring consistent product development across laboratories," Strych said. "We are pleased that this collaboration has made this resource broadly available to support coronavirus vaccine research worldwide." A full characterization report will be provided along with the antibody, detailing the specificity across different antigens and vaccine formats, based on data produced by Baylor and PATH. To help ensure equitable access, the antibody generated is available for a small handling charge and the cost of shipping for use by vaccine researchers and manufacturers who are developing vaccines for use in countries with low- and middle-income economies. Providing these open resources is one component of PATH's ongoing work with partners to advance the development of vaccines that are low-cost, broadly protective and tailored for use in low-resource settings. The SARS-CoV-1 antibody is available from MHRA via its online repository and distribution center. Visit www.nibsc.org or contact [email protected]. "Making this antibody available to the global vaccine development and manufacturing community - at minimal cost for vaccines targeted toward low-resource economies - can help clear hurdles and accelerate efforts to bring a SARS-CoV-1 vaccine to market," said Dr. Jessica White, PATH senior scientist, Vaccine Formulation. "Though the COVID-19 pandemic is over, coronaviruses have not gone away and this will be a helpful too for future pandemic responses. PATH is proud to be part of this fruitful collaboration and to be supporting researchers in their work to expand coronavirus vaccine development." PATH, Baylor and the MHRA previously collaborated to make SARS-CoV-2 antibodies specific to the Wuhan, Omicron, and Delta variants available to researchers. Funding for SARS-CoV-1 antibody development was provided to PATH from the Coalition for Epidemic Preparedness Innovations.

New typhoid conjugate vaccine from EuBiologics receives WHO prequalification. August 26, 2026 by PATH This important milestone could provide countries with an additional option for typhoid vaccination and can contribute to a sustainable supply of typhoid conjugate vaccines. Seattle, United States and Seoul, Republic of Korea - EuTYPH-C Inj.(R) Multi-dose, a new typhoid conjugate vaccine (TCV) manufactured by EuBiologics in the Republic of Korea, has been prequalified by the World Health Organization (WHO). This brings the total number of WHO-prequalified TCVs to five and represents another important step toward expanding global access to typhoid vaccination. Demand for TCVs is high in typhoid-endemic countries. TCVs, recommended by WHO, have several advantages compared to older typhoid vaccines; notably, they provide longer-lasting protection, only require one dose, and can be given to children as young as 6 months of age, allowing for inclusion in routine immunization. However, TCVs are not always affordable or accessible for low-income countries. Development of additional TCVs from diverse manufacturers can help strengthen supply, support greater affordability, and expand access for countries seeking to introduce TCVs as part of their typhoid prevention and control strategies. "WHO prequalification of EuTYPH-C Inj.(R) Multi-dose is an important milestone in EuBiologics' commitment to expanding access to high-quality vaccines worldwide," said Howard Her, Clinical Development Team Leader at EuBiologics. "We are grateful to RIGHT Foundation, PATH, and all of our clinical and development partners whose collaboration made this achievement possible. We look forward to contributing to a sustainable global supply of typhoid conjugate vaccines and helping countries protect more children and communities from typhoid fever." WHO prequalification - a designation confirming that a vaccine meets strict international standards for quality, safety, and efficacy - was supported by rigorous clinical studies in the Philippines, Kenya, and Senegal that demonstrated strong safety and immunogenicity. Importantly, WHO prequalification enables EuTYPH-C Inj.(R) Multi-dose to be considered for procurement by United Nations agencies and for use in Gavi, the Vaccine Alliance-supported immunization programs. It is approved for use in children and adults aged 6 months to 45 years. PATH supported the EuTYPH-C Inj.(R) Multi-dose Phase 3 clinical study in Kenya and Senegal, as well as supported EuBiologics through WHO prequalification pre-submission meetings and clinical assessment responses. PATH is now collaborating with EuBiologics on a follow-up study evaluating the persistence of immune responses approximately 3 to 3.5 years after vaccination among children who participated in the previous Phase 3 study. Final results from the study are expected in early 2027. "The ongoing evolution of new TCVs onto the global market is crucial for establishing sustainable, accessible supply in the regions with the greatest need. Prequalification of EuTYPH-C Inj.(R) Multi-dose marks the moment when rigorous clinical research transforms into real, lifesaving protection for children in typhoid endemic regions," said Dr. Emmanuel Mugisha, Global Director of Vaccine Implementation and Director of TyVAC at PATH, a consortium that aims to accelerate the introduction of TCVs in Gavi-eligible typhoid-endemic countries. "PATH congratulates EuBiologics on this milestone and is proud of the work we've done together to strengthen the TCV toolkit." Typhoid is a serious and potentially life-threatening illness that primarily impacts children younger than 15 years of age in Asia and sub-Saharan Africa. The Global Burden of Disease Study estimated that typhoid caused approximately 6.2 million cases and 72,000 deaths globally in 2023. While typhoid is treatable with antibiotics, drug-resistant typhoid is increasing, raising the urgency for preventative measures including TCVs and improvements to water, sanitation, and hygiene. Millions of children have already been reached through TCV introduction campaigns worldwide. About PATH PATH is a global nonprofit dedicated to achieving health equity. With nearly 50 years of experience forging multisector partnerships, and with expertise in science, economics, technology, advocacy, and dozens of other specialties, PATH develops and scales up innovative solutions to the world's most pressing health challenges. For more information, visit https://www.path.org. About EuBiologics Co., Ltd. EuBiologics Co., Ltd., headquartered in Seoul, Republic of Korea, is a specialized developer of both preventive and therapeutic vaccines. The company is focused on building a diverse pipeline that includes bacterial and viral vaccines for infectious disease prevention, as well as personalized therapeutic vaccines. EuBiologics Co., Ltd. is a major supplier of WHO-prequalified oral cholera vaccines through UNICEF procurement, playing a key role in the global public health market. Leveraging its proprietary vaccine platforms, the company is also advancing premium vaccine development and provides customized contract research and manufacturing services for biopharmaceutical products. For more information, please visit the website (http://eubiologics.com/eng/).

Port Authority awards $10 million contract to Wi-Tronix for new onboard technology to improve maintenance of railcar fleet. August 25, 2026 Real-time monitoring will help PATH identify and address railcar problems faster, keeping more trains in service and reducing delays for riders. New system creates a single connected platform for onboard train data, replacing time-consuming manual retrieval and supporting federal compliance. The Port Authority of New York and New Jersey has awarded a $10 million contract to Wi-Tronix to deploy new onboard technology across the railcar fleet for the PATH commuter rail. The investment will support PATH's regulatory compliance and improve service reliability for millions of riders by providing real-time visibility of onboard mechanical issues of each railcar. The Wi-Tronix technology supports PATH's compliance with Federal Railroad Administration (FRA) requirements, including a FAST Act mandate for onboard image and audio recording. By modernizing how this information is captured and accessed, PATH can retrieve data remotely, respond more efficiently to breakdowns and improve car availability during service disruptions, resulting in fewer delays. PATH will install the Wi-Tronix technology on more than half of PATH's fleet of 422 cars, with installation and implementation expected to be complete by the FRA deadline in October 2027. Through its partnership with the private-public Transit Tech Lab, PATH has increasingly embraced new technology in its operations as the 118-year-old commuter railroad modernizes its operations, from daily service to maintenance to customer communications. The Transit Tech Lab, which is managed by the Partnership Fund for New York City, provides a pathway for New York City-area transit agencies to test innovative technologies that address operational challenges. The contract award follows a multi-year collaboration that began in 2023 through the Transit Tech Lab program, allowing PATH to evaluate Wi-Tronix's technology in a live transit environment. The PATH tests expanded to a larger deployment of the Wi-Tronix technology after a 30-month pilot. The contract includes Wi-Tronix's continued maintenance and upkeep of the technology. "A safe and reliable PATH system is essential to the region's economy and to the continued growth of communities like Jersey City, Harrison, Newark and Hoboken," said Port Authority Chairman Kevin O'Toole. "Modernizing a 118-year-old railroad means investing not only in its physical infrastructure, but in new technology that helps us provide better, more reliable service for every rider." "We've invested heavily in PATH's physical infrastructure in the past two years and now we're building on that work with technology that can help us operate the railroad more efficiently," said Port Authority Executive Director Kathryn Garcia. "Giving our teams better information faster means they can address problems quicker and provide more reliable service for PATH riders." "This unique partnership between PATH and Wi-Tronix, powered by Transit Tech Lab, is a potential game-changer that will raise our operational, safety, and maintenance standards to a new level," said PATH General Manager/Director Clarelle DeGraffe. "By advancing real-time visibility of PATH's railcar fleet, we're enhancing a legacy system to transform it into a more responsive system that will move riders more safely and efficiently." "Transit Tech Lab was created to help transit agencies accelerate innovation and address real-world challenges," said Stacey Matlen, senior vice president of innovation at the Partnership for New York City. "We're proud to have helped facilitate this partnership between PATH and Wi-Tronix and look forward to seeing how this multi-year collaboration will support reliability and create a better experience for riders." "This investment reflects a shift toward more connected real-time transit operations," said Larry Jordan, Wi-Tronix president and CEO. "By making onboard information available when and where it's needed, PATH can respond more quickly, improve reliability, and continue delivering safe, dependable service to its riders." The $10 million contract award to Wi-Tronix builds on the successful completion of the Port Authority's two-year, $430 million PATH Forward program to rehabilitate PATH's railcars, tracks, stations and other critical infrastructure. PATH Forward, which was completed in spring 2026, prepared the railroad to increase service to its most significant levels in more than two decades, adding service to all four PATH lines for late-night and weekend riders and increasing capacity on three lines. PATH replaced more than 15,000 feet of track, installed three new rail switch systems, upgraded four stations, and improved reliability of its railcars by nearly 13 percent from an average of 95,900 miles between failures before PATH Forward to 108,130 miles by spring 2025. About Wi-Tronix. Wi-Tronix delivers advanced IoT platforms for the rail industry and provides actionable information and insights on how rail networks are performing in real time. By enabling continuous improvement with a powerful combination of connectivity, analytics, alerts, and more, Wi-Tronix is enabling freight, passenger railroads, and transit systems with the tools that help enhance safety, operational efficiency, and service reliability. The Wi-Tronix team is passionately committed to its global vision of saving lives and ensuring the most efficient and reliable movement of goods and people throughout the world. Find out more at www.wi-tronix.com. About The Port Authority of New York and New Jersey. The Port Authority of New York and New Jersey is a bi-state agency that builds, operates and maintains many of the most important transportation and trade infrastructure assets in the country. For over a century, the agency's network of major airports; critical bridges, tunnels and bus terminals; a commuter rail line; and the busiest seaport on the East Coast has been among the most vital in the country - transporting hundreds of millions of people and moving essential goods into and out of the region. The Port Authority also owns and manages the 16-acre World Trade Center campus, which welcomes tens of thousands of office workers and millions of annual visitors. The agency's historic $45 billion capital plan for 2026-2035 advances a new generation of projects that will modernize, strengthen, and expand the agency's infrastructure around the region, including: a new Midtown Bus Terminal, transformations at John F. Kennedy International Airport (JFK) and Newark Liberty International Airport (EWR), and a new era for PATH, with major service increases. The Port Authority's annual budget of $10 billion includes no tax revenue from either the states of New York or New Jersey or from the city of New York. The agency raises the necessary funds for the improvement, construction or acquisition of its facilities primarily on its own credit. For more information, visit the Port Authority's press room.